<span item_type="fundamental" item_id="150a08911309f99d5dc0c5cf0beeb79c" counter_id="ST/US/VVOS" env="prod"></span><span item_type="announcement" item_id="637882073728420993" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 17.44 M.</p><p>EPS: As of FY2025, the actual value is USD -2.07.</p><p></p><h4>Revenue</h4><p>Vivos Therapeutics, Inc. reported total revenue of $17,443 thousand for the year ended December 31, 2025, an increase of 16% from $15,031 thousand in 2024, primarily driven by higher sleep testing services and revenue from OSA patient treatment at two Nevada locations of The Sleep Center of Nevada (SCN), which Vivos Therapeutics, Inc. acquired in June 2025, partially offset by the wind-down of Vivos Integrated Practice (VIP) enrollment revenue <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>. Product revenue was $6,487 thousand in 2025, down from $7,874 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>. Service revenue increased to $10,956 thousand in 2025 from $7,157 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>.</p><h4>Gross Profit and Margin</h4><p>Gross profit for Vivos Therapeutics, Inc. was $10,542 thousand for the year ended December 31, 2025, an increase of 17% from $9,019 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>. The gross margin remained consistent at 60% for both 2025 and 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>.</p><h4>Operating Expenses</h4><p>Total operating expenses for Vivos Therapeutics, Inc. increased to $30,436 thousand in 2025 from $20,190 thousand in 2024, partly due to costs associated with integrating and managing SCN operations and related OSA treatment centers <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>. General and administrative expenses were $27,727 thousand in 2025, up from $17,878 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>. Sales and marketing expenses decreased to $1,400 thousand in 2025 from $1,731 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>. Depreciation and amortization increased to $1,309 thousand in 2025 from $581 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>.</p><h4>Operating Loss</h4><p>Vivos Therapeutics, Inc. reported an operating loss of - $19,894 thousand for 2025, compared to an operating loss of - $11,171 thousand for 2024, reflecting upfront investments in the new business model and the SCN acquisition <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>.</p><h4>Net Loss</h4><p>Net loss for Vivos Therapeutics, Inc. was - $21,230 thousand for 2025, compared to - $11,136 thousand for 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>. The net loss attributable to stockholders was - $21,170 thousand in 2025, compared to - $11,136 thousand in 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>.</p><h4>Cash and Cash Equivalents</h4><p>Cash and cash equivalents for Vivos Therapeutics, Inc. were $2,029 thousand as of December 31, 2025, down from $6,260 thousand as of December 31, 2024 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>. Subsequent to year-end, the company’s cash position was augmented by two financing transactions for aggregate gross proceeds of $6,800 thousand <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>.</p><h4>Business Strategy Shift</h4><p>Vivos Therapeutics, Inc.’s 2025 results reflect a continued pivot in business strategy, moving away from enrolling and training VIP dentists to sell proprietary OSA treatments <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>. The new strategy focuses on contractual alliances with and outright acquisitions of sleep specialty medical providers, sleep testing centers, and similar entities <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>.</p><h4>Outlook/Guidance</h4><p>Vivos Therapeutics, Inc. anticipates that strategic actions, including significant cost-savings initiatives and a strengthened capital structure, will position the company for higher top-line growth and better contribution margins <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>. The company aims to achieve cash flow positive operations by the end of 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1716166/000149315226016865/ex99-1.htm"></span>.</p>

Vivos Therapeutics | 8-K: FY2025 Revenue: USD 17.44 M